Acknowledgement
Supported by : Radiological Research Foundation of Korea, National Research Foundation of Korea (NRF)
References
- Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, et al. Global cancer facts and figures 2007. Atlanta: American Cancer Society, 2007
- Survival rates for stomach cancer, by stage. Cancer.org Web site. https://www.cancer.org/cancer/stomach-cancer/detection-diagnosis-staging/survival-rates.html. Accessed February 5, 2017
- Stomach cancer survival. Cancerresearchuk.org Web site. http://www.cancerresearchuk.org/about-cancer/stomachcancer/survival. Accessed February 5, 2017
- Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51 https://doi.org/10.1056/NEJMra043186
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672 https://doi.org/10.1056/NEJMoa052306
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792 https://doi.org/10.1056/NEJM200103153441101
- Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369:29-36 https://doi.org/10.1016/S0140-6736(07)60028-2
- Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278 https://doi.org/10.1093/annonc/mdi064
- Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-1529 https://doi.org/10.1093/annonc/mdn169
- Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805 https://doi.org/10.1111/j.1365-2559.2008.03028.x
- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697 https://doi.org/10.1016/S0140-6736(10)61121-X
- Kim SH, Kim SH, Kim MA, Shin CI, Han JK, Choi BI. CT differentiation of poorly-differentiated gastric neuroendocrine tumours from well-differentiated neuroendocrine tumours and gastric adenocarcinomas. Eur Radiol 2015;25:1946-1957 https://doi.org/10.1007/s00330-015-3600-z
- Kim JW, Shin SS, Heo SH, Lim HS, Lim NY, Park YK, et al. The role of three-dimensional multidetector CT gastrography in the preoperative imaging of stomach cancer: emphasis on detection and localization of the tumor. Korean J Radiol 2015;16:80-89 https://doi.org/10.3348/kjr.2015.16.1.80
- He J, Shi H, Zhou Z, Chen J, Guan W, Wang H, et al. Correlation between apparent diffusion coefficients and HER2 status in gastric cancers: pilot study. BMC Cancer 2015;15:749 https://doi.org/10.1186/s12885-015-1726-7
- Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393 https://doi.org/10.1016/j.humpath.2007.02.005
- Ahn HS, Kim SH, Kodera Y, Yang HK. Gastric cancer staging with radiologic imaging modalities and UICC staging system. Dig Surg 2013;30:142-149 https://doi.org/10.1159/000350881
- Park HS, Lee JM, Kim SH, Lee JY, Yang HK, Han JK, et al. Three-dimensional MDCT for preoperative local staging of gastric cancer using gas and water distention methods: a retrospective cohort study. AJR Am J Roentgenol 2010;195:1316-1323 https://doi.org/10.2214/AJR.10.4320
- Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd English edition. Gastric Cancer 1998;1:10-24 https://doi.org/10.1007/PL00011681
- Badescu A, Georgescu CV, Vere CC, Craitoiu S, Grigore D. Correlations between Her2 oncoprotein, VEGF expression, MVD and clinicopathological parameters in gastric cancer. Rom J Morphol Embryol 2012;53:997-1005
- Schoppmann SF, Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, et al. HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer. Ann Oncol 2010;21:955-960 https://doi.org/10.1093/annonc/mdp532
- Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006;51:1371-1379 https://doi.org/10.1007/s10620-005-9057-1
- Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg 2009;33:2112-2118 https://doi.org/10.1007/s00268-009-0142-z
- Lemoine NR, Jain S, Silvestre F, Lopes C, Hughes CM, McLelland E, et al. Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 1991;64:79-83 https://doi.org/10.1038/bjc.1991.243
- Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-777 https://doi.org/10.1016/j.humpath.2008.11.014
Cited by
- Age of Data in Contemporary Research Articles Published in Representative General Radiology Journals vol.19, pp.6, 2018, https://doi.org/10.3348/kjr.2018.19.6.1172
- Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer vol.10, pp.6, 2017, https://doi.org/10.4251/wjgo.v10.i6.124
- Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer vol.83, pp.3, 2017, https://doi.org/10.1007/s00280-018-3753-y
- Relationship between CT characteristics and human epidermal growth factor receptor 2 expression in gastric cancers vol.3, pp.3, 2020, https://doi.org/10.1007/s42058-020-00041-3
- Mevalonate pathway as a novel target for the treatment of metastatic gastric cancer vol.20, pp.6, 2017, https://doi.org/10.3892/ol.2020.12183
- CT-detected extramural venous invasion is corelated with presence of lymph node metastasis and progression-free survival in gastric cancer vol.93, pp.1116, 2017, https://doi.org/10.1259/bjr.20200673
- Dual-Energy CT-Based Nomogram for Decoding HER2 Status in Patients With Gastric Cancer vol.216, pp.6, 2021, https://doi.org/10.2214/ajr.20.23528